超声及临床病理特征对甲状腺乳头状癌Delphian淋巴结转移的诊断价值

doi:10.3760/cma.j.issn.1007-1245.2024.17.026

摘要/Abstract

摘要：

目的　探究超声及临床病理特征对甲状腺乳头状癌（papillary thyroid carcinoma，PTC）Delphian淋巴结（Delphian lymph node，DLN）转移的诊断价值。方法　选择2021年2月至2023年8月铜川市人民医院收治的120例PTC患者作为研究对象，其中男36例，女84例，年龄（43.69±6.85）岁。按有无DLN转移分为转移组与对照组（未转移）。两组均进行超声检查，收集其超声及临床病理特征信息，分析影响患者DLN转移的因素，并采用受试者操作特征曲线（receiver operating characteristic curve，ROC）评估超声及临床病理特征对患者DLN转移的诊断效能。采用t检验、秩和检验、χ²检验。结果　120例PTC患者共检出145个病灶，DLN未转移患者共93个病灶，DLN转移患者共52个病灶。转移组与对照组在年龄［>45岁：30.56%（11/36）比54.76%（46/84）］、肿瘤部位［峡部及侧叶上1/3：67.31%（35/52）比21.51%（20/93）］、纵径［≥10 mm：59.62%（31/52）比38.71%（36/93）］、纵横比［≥1：55.77%（29/52）比32.26%（36/93）］、多病灶［41.67%（21/36）比20.24%（67/84）］、被膜侵犯［63.46%（33/52）比40.86%（38/93）］、非喉前中央区淋巴结转移［53.85%（24/52）比31.18%（64/93）］方面相比，差异均有统计学意义（χ²=5.921、29.718、5.864、7.639、5.917、6.818、7.180，均P<0.05）。logistic回归分析结果显示，肿瘤在峡部及侧叶上1/3、纵横比≥1、有被膜侵犯、非喉前中央区淋巴结转移为PTC患者DLN转移的危险因素（OR=3.267、7.576、3.130、8.306，均P<0.05）。ROC显示，联合诊断的曲线下面积（area under the curve，AUC）、灵敏度、特异度分别为0.775、67.31%、78.49%；肿瘤部位、纵横比、被膜侵犯及非喉前中央区淋巴结转移的AUC分别为0.729、0.618、0.613、0.613（均P<0.05）。结论　PTC患者超声及临床病理特征中，肿瘤在峡部及侧叶上1/3、纵横比≥1、有被膜侵犯、非喉前中央区淋巴结转移为患者DLN转移的危险因素，且其联合具有较高的诊断价值。

关键词:

甲状腺癌, 淋巴结转移, 超声, 临床病理特征, 诊断价值

Abstract:

Objective　To explore the diagnostic value of ultrasound and clinical pathological features for Delphian lymph node (DLN) metastasis in patients with papillary thyroid carcinoma (PTC). Methods　One hundred and twenty patients with PTC treated at Tongchuan People's Hospital from February 2021 to August 2023 were selected as the study objects, including 36 males and 84 females who were (43.69±6.85) years old. They were divided into a metastatic group and a control group (without metastasis) based on the presence or absence of DLN metastasis. Both groups underwent ultrasound examination. The information on their ultrasound and clinical pathological features was collected. The factors affecting DLN metastasis in the patients were analyzed. The diagnostic efficacy of ultrasound and clinical pathological features for DLN metastasis in the patients was evaluated using the receiver operating characteristic curve (ROC). t test, rank sum test, and χ² test were applied. Results　A total of 145 lesions were detected in the 120 patients. There were 93 lesions in the patients without DLN metastasis and 52 lesions in the patients with DLN metastasis. There statistical differences between the metastatic group and the control group in terms of age [>45 years: 30.56% (11/36) vs. 54.76% (46/84)], tumor location [isthmus and upper lobe 1/3: 67.31% (35/52) vs. 21.51% (20/93)], longitudinal diameter [≥10 mm: 59.62% (31/52) vs. 38.71% (36/93)], aspect ratio [≥1: 55.77% (29/52) vs. 32.26% (36/93)], multiple lesions [41.67% (21/36) vs. 20.24% (67/84)], capsule invasion [63.46% (33/52) vs. 40.86% (38/93)], and lymph node metastasis in the non-central area of the larynx [53.85% (24/52) vs. 31.18% (64/93)] (χ²=5.921, 29.718, 5.864, 7.639, 5.917, 6.818, and 7.180; all P<0.05). The results of logistic regression analysis showed that the risk factors for DLN metastasis in the patients with PTC were tumors located in the isthmus and upper one-third of the lateral lobe, aspect ratio ≥ 1, capsule invasion, and lymph node metastasis in the non-central area of the larynx (OR=3.267, 7.576, 3.130, and 8.306; all P<0.05). The ROC displayed the area under the curve (AUC), sensitivity, and specificity of the combination were 0.775, 67.31%, and 78.49%, respectively. The AUC's of tumor location, aspect ratio, capsule invasion, and lymph node metastasis in the non-central area of the larynx were 0.729, 0.618, 0.613, and 0.613 (all P<0.05). Conclusions　Among the ultrasound and clinical pathological features of patients with PTC, the presence of tumors in the isthmus and upper 1/3 of the lateral lobe, aspect ratio ≥ 1, capsule invasion, and lymph node metastasis in the non-central area of the larynx are risk factors for DLN metastasis; their combination has high diagnostic value.

Key words:

Thyroid cancer, Lymph node metastasis, Ultrasound, Clinical pathological features, Diagnostic value

折文利徐鑫利李彦婷李新.

超声及临床病理特征对甲状腺乳头状癌Delphian淋巴结转移的诊断价值 [J]. 国际医药卫生导报, 2024, 30(17): 2951-2956.

Zhe Wenli, Xu Xinli, Li Yanting, Li Xin.

Diagnostic value of ultrasound and clinical pathological features for Delphian lymph node metastasis in patients with papillary thyroid carcinoma [J]. International Medicine and Health Guidance News, 2024, 30(17): 2951-2956.

参考文献

[1] Xu S, Huang H, Huang Y, et al. Comparison of lobectomy vs total thyroidectomy for intermediate-risk papillary thyroid carcinoma with lymph node metastasis[J]. JAMA Surg, 2023, 158(1):73-79. DOI: 10.1001/jamasurg. 2022.5781.
[2] Tang L, Qu RW, Park J, et al. Prevalence of occult central lymph node metastasis by tumor size in papillary thyroid carcinoma: a systematic review and meta-analysis [J]. Curr Oncol, 2023, 30(8): 7335-7350. DOI: 10.3390/curroncol30080532.
[3] 丁金旺,彭友,潘钢,等. 甲状腺乳头状癌Delphian淋巴结清扫的临床意义[J]. 中华内分泌外科杂志, 2020, 14(4): 290-294. DOI: 10.3760/cma.j.issn.115807-20190305- 00040.
[4] 刘威,王聪,王正林,等.单侧甲状腺乳头状癌Delphian淋巴结转移的发生率及其临床意义[J].外科理论与实践, 2021, 26(5): 445-448. DOI: 10.16139/j.1007-9610.2021.05.017.
[5] 齐琴,陈巧玲,石灵芳. 基于超声特征建立甲状腺乳头状癌中央区淋巴结转移的列线图模型[J]. 山西医药杂志,2023,52(5):332-336. DOI: 10.3969/j.issn.0253-9926. 2023.05.003.
[6] 孙斌,张明博,罗渝昆. 超声新技术预测甲状腺乳头状癌颈部淋巴结转移的研究现状与展望[J]. 中国医学科学院学报,2023,45(4):672-676. DOI: 10.3881/j.issn. 1000-503X.15073.
[7] 颜海波,夏中平,陈善,等. 甲状腺乳头状癌Delphian淋巴结转移的危险因素[J]. 外科理论与实践,2022,27(5):453-457. DOI:10.16139/j.1007-9610.2022.05.014.
[8] Zhu J, Huang R, Yu P, et al. Clinical implications of Delphian lymph node metastasis in papillary thyroid carcinoma[J]. Gland Surg, 2021, 10(1):73-82. DOI: 10.21037/gs-20-521.
[9] Wang B, Wen XZ, Zhang W, et al. Clinical implications of Delphian lymph node metastasis in papillary thyroid carcinoma: a single-institution study, systemic review and meta-analysis[J]. J Otolaryngol Head Neck Surg, 2019, 48(1):42. DOI: 10.1186/s40463-019-0362-7.
[10] Iyer NG, Kumar A, Nixon IJ, et al. Incidence and significance of Delphian node metastasis in papillary thyroid cancer[J]. Ann Surg, 2011, 253(5):988-91. DOI: 10.1097/SLA.0b013e31821219ca.
[11] 张传灼,高国宇,任明. 甲状腺乳头状癌不同位置颈侧区淋巴结转移率及跳跃性转移特征分析[J]. 徐州医科大学学报, 2019, 39(3): 172-175. DOI: 10.3969/j.issn.2096-3882. 2019.03.004.
[12] Alibakhshi A, Sheikhi S, Meshkati Yazd SM, et al. The incidence and features of Delphian lymph node involvement in patients with papillary thyroid carcinoma[J]. BMC Surg, 2022, 22(1): 320. DOI: 10.1186/s12893-022-01742-5.
[13] 康韶洋,胡晓东,聂智梅,等. 甲状腺乳头状癌颈部淋巴结转移的危险因素分析——单中心回顾性研究[J]. 解放军医学杂志,2023,48(5):510-515. DOI: 10.11855/j.issn. 0577-7402.2023.05.0510.
[14] 王美,王雪格,李利梅. 甲状腺乳头状癌颈部淋巴结转移特征及相关影响因素研究[J]. 实用癌症杂志,2022,37(3):520-522. DOI: 10.3969/j.issn.1001-5930.2022.03.048.
[15] 王金秋,张立,章佳波,等. 甲状腺乳头状微小癌cN0期中央区淋巴结转移相关因素分析[J]. 中华内分泌外科杂志,2020,14(4):279-283. DOI: 10.3760/cma.j.issn. 115807-20191103-00213.
[16] Zhao J, Zhang Y, Zheng X. Clinicopathological characteristics of papillary thyroid cancer located in the isthmus with Delphian lymph node metastasis[J]. Br J Oral Maxillofac Surg, 2022, 60(5):635-638. DOI: 10.1016/j.bjoms.2021.11.016.
[17] Chai YJ, Kim SJ, Choi JY, et al. Papillary thyroid carcinoma located in the isthmus or upper third is associated with Delphian lymph node metastasis[J]. World J Surg. 2014 ,38(6):1306-11. DOI: 10.1007/s00268-013-2406-x.
[18] Li X, Duan Y, Liu D, et al. Diagnostic model incorporating clinicopathological characteristics of Delphian lymph node metastasis risk profiles in papillary thyroid cancer[J]. Front Endocrinol (Lausanne), 2021,12: 591015. DOI: 10.3389/fendo.2021.591015.
[19] Yan Y, Wang Y, Liu N, et al. Predictive value of the Delphian lymph node in cervical lymph node metastasis of papillary thyroid carcinoma[J]. Eur J Surg Oncol, 2021, 47(7):1727-1733. DOI:10.1016/j.ejso.2021.02.010.
[20] He Q, Zhu Q, Dong J, et al. The clinical value of Delphian lymph node metastasis in papillary thyroid carcinoma[J]. Asian J Surg, 2020, 43(12): 1180-1181. DOI:10.1016/j.asjsur.2020.09.008.
[21] Zuo Q, Chen X, Yang J, et al. Analysis of the clinical value of Delphian lymph node metastasis in papillary thyroid carcinoma[J]. J Oncol, 2022:8108256. DOI: 10.1155/2022/8108256.
[22] 周娜,王蓓,徐秀梅,等. 常规超声联合临床病理特征列线图对mPTC喉前淋巴结转移的预测价值[J]. 重庆医学,2023,52(19):2892-2898. DOI:10.3969/j.issn.1671-8348. 2023.19.003.
[23] 颜炜. 648例甲状腺乳头状癌Delphian淋巴结转移与临床病理因素相关性分析[D]. 长春:吉林大学,2020.